Deerfield Management’s Sage Therapeutics SAGE Stock Holding History

Deerfield Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-68,000	Closed	-$4.24M	–	102
2017 Q3	$4.24M	Buy	+68,000	New	+$5.34M	0.19%	82
2017 Q2	–	Sell	-122,000	Closed	-$8.67M	–	92
2017 Q1	$8.67M	Buy	+122,000	New	+$7.15M	0.33%	74
2016 Q2	–	Sell	-1,113,654	Closed	-$35.7M	–	115
2016 Q1	$35.7M	Buy	1,113,654 +514,800	+86%	+$18.1M	1.52%	25
2015 Q4	$34.9M	Sell	598,854 -50,210	-8%	-$2.49M	1.42%	20
2015 Q3	$27.5M	Buy	649,064 +344,064	+113%	+$21.2M	1.06%	38
2015 Q2	$22.3M	Sell	305,000 -290,443	-49%	-$18.7M	0.74%	49
2015 Q1	$29.9M	Buy	595,443 +332,818	+127%	+$14.3M	0.97%	29
2014 Q4	$9.61M	Sell	262,625 -188,042	-42%	-$7.01M	0.35%	61
2014 Q3	$14.2M	Buy	+450,667	New	+$13.1M	0.52%	58

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Deerfield Management's SAGE Position: Q4 2017 in Review

Deerfield Management sold out of Sage Therapeutics (SAGE) in Q4 2017, closing a stake of 68,000 shares — an estimated $4.24M sold.

Deerfield Management first reported a position in SAGE in Q3 2014 and held it in 9 quarters. The position peaked at $35.7M in Q1 2016. 224 funds tracked by Wall St. Rank hold SAGE as of Q4 2017.

Deerfield Management reported no remaining Sage Therapeutics position as of Q4 2017 after selling out during the quarter.
Deerfield Management sold 68,000 Sage Therapeutics shares in Q4 2017, an estimated $4.24M.
Deerfield Management first reported a position in Sage Therapeutics in Q3 2014 and held it in 9 quarters.
Deerfield Management's Sage Therapeutics position peaked at $35.7M in Q1 2016.
224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2017.

Based on Deerfield Management's 13F filing for Q4 2017, filed 14 Feb 2018.